NEW YORK (GenomeWeb) – EKF Diagnostics today announced that it has received a $110 million offer from an undisclosed buyer for its point-of-care diagnostics business.

The firm has received a non-binding preliminary proposal for the business, which excludes its clinical chemistry and molecular diagnostics businesses. The offer is one of the results from a strategic review initiated April 2 by the firm's board of directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.